These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 10371571

  • 1. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
    Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, Gastaut JA, Oksenhendler E, Boumsell L, Gomard E, Rabian C, Weiss L, Guillet JG, Delfraissy JF, Aboulker JP, Seligmann M.
    Lancet; 1999 Jun 05; 353(9168):1923-9. PubMed ID: 10371571
    [Abstract] [Full Text] [Related]

  • 2. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
    Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, Leong WP, Raffanti SP, Wheeler DA, Anderson RD, Keiser P, Schrader SR, Goodgame JC, Steinhart CR, Murphy RL, Wolin MJ, Smith KA.
    HIV Clin Trials; 2000 Jun 05; 1(3):1-15. PubMed ID: 11590500
    [Abstract] [Full Text] [Related]

  • 3. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B, AIDS Clinical Trials Group 248 Study Team.
    J Acquir Immune Defic Syndr; 2004 May 01; 36(1):576-87. PubMed ID: 15097300
    [Abstract] [Full Text] [Related]

  • 4. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, Lopardo G, Salomon H, Saracco M, Nelson E, Law MG, Davey RT, Allende MC, Lane HC.
    J Infect Dis; 2000 May 01; 181(5):1614-21. PubMed ID: 10823761
    [Abstract] [Full Text] [Related]

  • 5. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial.
    Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA, Goujard C, Rouzioux C, Maral J, Delfraissy JF, Emilie D, Aboulker JP, ANRS 079 Study Group.
    AIDS; 2003 Feb 14; 17(3):343-51. PubMed ID: 12556688
    [Abstract] [Full Text] [Related]

  • 6. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
    Davey RT, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG, Dewar RL, Sahner DK, Duliege AM, Capra WB, Leong WP, Giedlin MA, Lane HC, Kahn JO.
    JAMA; 2000 Jul 12; 284(2):183-9. PubMed ID: 10889591
    [Abstract] [Full Text] [Related]

  • 7. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
    Hengge UR, Goos M, Esser S, Exner V, Dötterer H, Wiehler H, Borchard C, Müller K, Beckmann A, Eppner MT, Berger A, Fiedler M.
    AIDS; 1998 Dec 03; 12(17):F225-34. PubMed ID: 9863864
    [Abstract] [Full Text] [Related]

  • 8. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB, AIDS Clinical Trials Group 328 Study Team.
    Arch Intern Med; 2007 Mar 26; 167(6):597-605. PubMed ID: 17389292
    [Abstract] [Full Text] [Related]

  • 9. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
    Simonelli C, Zanussi S, Sandri S, Comar M, Lucenti A, Talamini R, Bortolin MT, Giacca M, De Paoli P, Tirelli U.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan 01; 20(1):20-7. PubMed ID: 9928725
    [Abstract] [Full Text] [Related]

  • 10. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
    Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC.
    N Engl J Med; 1996 Oct 31; 335(18):1350-6. PubMed ID: 8857018
    [Abstract] [Full Text] [Related]

  • 11. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
    Pakker NG, Kroon ED, Roos MT, Otto SA, Hall D, Wit FW, Hamann D, van der Ende ME, Claessen FA, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CH, Sprenger HG, Weigel HM, Montaner JS, Lange JM, Reiss P, Schellekens PT, Miedema F.
    AIDS; 1999 Feb 04; 13(2):203-12. PubMed ID: 10202826
    [Abstract] [Full Text] [Related]

  • 12. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.
    Larsen CS, Ostergård L, Møller BK, Buhl MR.
    Scand J Infect Dis; 2000 Feb 04; 32(2):153-60. PubMed ID: 10826900
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
    Simonelli C, Zanussi S, Comar M, Vaccher E, Giacca M, De Paoli P, Tirelli U.
    AIDS; 1998 Jan 01; 12(1):112-3. PubMed ID: 9456263
    [No Abstract] [Full Text] [Related]

  • 14. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.
    Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D, ILSTIM.
    AIDS; 2002 Oct 18; 16(15):2027-34. PubMed ID: 12370501
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
    Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, Brambilla A, Vicenzi E, Carrera P, Racca S, Soldini L, Gianotti N, Murone M, Veglia F, Poli G, Lazzarin A.
    J Infect Dis; 2001 May 15; 183(10):1476-84. PubMed ID: 11319683
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.
    Arnó A, Ruiz L, Juan M, Jou A, Balagué M, Zayat MK, Marfil S, Martínez-Picado J, Martínez MA, Romeu J, Pujol-Borrell R, Lane C, Clotet B.
    J Infect Dis; 1999 Jul 15; 180(1):56-60. PubMed ID: 10353861
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-2 therapy in patients with HIV infection.
    INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.
    N Engl J Med; 2009 Oct 15; 361(16):1548-59. PubMed ID: 19828532
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study.
    Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC.
    J Infect Dis; 1993 Mar 15; 167(3):519-25. PubMed ID: 8095058
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Mar 15; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 20. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Mar 15; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.